Vertex Pharmaceuticals Authorizes $4 Billion In Additional Share Repurchases

 Vertex Pharmaceuticals has authorized an additional share repurchase program of up to $4 billion.

The program does not have an expiration date and can be discontinued at any time, the Boston-based company said.

The biotechnology company in 2023 authorized a program to repurchase up to $3 billion in stock. As of this week, about $775 million remained in that program. The newly authorized program will add to that total.

https://www.morningstar.com/news/dow-jones/202505199289/vertex-pharmaceuticals-authorizes-4-billion-in-additional-share-repurchases